LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Search

Charles River Laboratories International Inc

Geschlossen

BrancheGesundheitswesen

166.05 1.65

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

159.38

Max

168.72

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.9M

56M

Verkäufe

-27M

1B

EPS

2.43

Gewinnspanne

5.529

Angestellte

18,700

EBITDA

-23M

198M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+26.93% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-862M

7.9B

Vorheriger Eröffnungskurs

164.4

Vorheriger Schlusskurs

166.05

Nachrichtenstimmung

By Acuity

5%

95%

149 / 351 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Charles River Laboratories International Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Feb. 2026, 23:07 UTC

Ergebnisse

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24. Feb. 2026, 23:01 UTC

Ergebnisse

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24. Feb. 2026, 22:59 UTC

Ergebnisse

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24. Feb. 2026, 22:42 UTC

Ergebnisse

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24. Feb. 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24. Feb. 2026, 23:48 UTC

Ergebnisse

OCBC's Fourth-Quarter Net Profit Rose on Higher Non-Interest Income

24. Feb. 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24. Feb. 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24. Feb. 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24. Feb. 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24. Feb. 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24. Feb. 2026, 23:16 UTC

Ergebnisse

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24. Feb. 2026, 23:13 UTC

Ergebnisse

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24. Feb. 2026, 23:12 UTC

Ergebnisse

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24. Feb. 2026, 23:10 UTC

Ergebnisse

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24. Feb. 2026, 23:10 UTC

Ergebnisse

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24. Feb. 2026, 23:08 UTC

Ergebnisse

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24. Feb. 2026, 23:07 UTC

Ergebnisse

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24. Feb. 2026, 22:52 UTC

Ergebnisse

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24. Feb. 2026, 22:46 UTC

Ergebnisse

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24. Feb. 2026, 22:31 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Receives New Bid From Paramount -- 3rd Update

24. Feb. 2026, 22:29 UTC

Ergebnisse

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24. Feb. 2026, 22:28 UTC

Ergebnisse

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24. Feb. 2026, 22:27 UTC

Ergebnisse

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24. Feb. 2026, 22:27 UTC

Ergebnisse

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24. Feb. 2026, 22:25 UTC

Ergebnisse

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24. Feb. 2026, 22:24 UTC

Ergebnisse

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24. Feb. 2026, 22:23 UTC

Ergebnisse

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24. Feb. 2026, 22:22 UTC

Ergebnisse

Woolworths Interim Dividend 45 Australian Cents/Share

24. Feb. 2026, 22:22 UTC

Ergebnisse

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

Peer-Vergleich

Kursveränderung

Charles River Laboratories International Inc Prognose

Kursziel

By TipRanks

26.93% Vorteil

12-Monats-Prognose

Durchschnitt 207.56 USD  26.93%

Hoch 265 USD

Tief 175 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Charles River Laboratories International Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

8

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

117.16 / 144.77Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

149 / 351 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat